TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31537110

Group type: EXPERIMENTAL
Intervention: Nasalance-based preclassification of oral-nasal balance disorders
Number of subjects: 54
Study: 31778601

Group type: EXPERIMENTAL
Intervention: esomeprazole (40 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: famotidine (40 mg/d)
Number of subjects: 160
Study: 28653499

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 1635
Study: 26380271

Group type: EXPERIMENTAL
Intervention: School-based mental health programme (20 hours total, 1 hour per week)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (8 classrooms)
Number of subjects: 308
Study: 22588377

Group type: EXPERIMENTAL
Intervention: Coping Cat program (cognitive-behavioral therapy; CBT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 22
Study: 22092484

Group type: EXPERIMENTAL
Intervention: Vitamin trial (Vitamin C = 500 mg/day + Vitamin E = 100 IU/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo trial
Number of subjects: 9
Study: 18852497

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Monitoring as a form of therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 9
Study: 16446018

Group type: EXPERIMENTAL
Intervention: Standardized knee-bends
Number of subjects: 17

Group type: COMPARATOR
Intervention: Unconstrained conditions
Number of subjects: 17
Study: 15244203

Group type: EXPERIMENTAL
Intervention: remifentanil/midazolam (n=18)
Number of subjects: 26

Group type: COMPARATOR
Intervention: tramadol/midazolam (n=18)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil/midazolam and tramadol/midazolam)
Number of subjects: 26
Study: 10831016

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 15900669

Group type: EXPERIMENTAL
Intervention: Constructions with wide interdental spaces
Number of subjects: 21

Group type: COMPARATOR
Intervention: Constructions with minimized interdental spaces
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (wide and minimized interdental spaces)
Number of subjects: 21
Study: 3964334

Group type: EXPERIMENTAL
Intervention: 50 mg t.i.d. indometacin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 60 mg t.i.d. acemetacin
Number of subjects: 16
Study: 29787532

Group type: EXPERIMENTAL
Intervention: Brief intervention focusing on symptom education, coping strategies, and utilizing supports
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received a 3-minute educational brochure review
Number of subjects: 0
Study: 27818598

Group type: EXPERIMENTAL
Intervention: 22-gauge aspiration needle (AN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 22-gauge core biopsy needle (PC)
Number of subjects: 56
Study: 24408976

Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469

Group type: COMPARATOR
Intervention: Progressive addition lenses
Number of subjects: 469
Study: 22773263

Group type: EXPERIMENTAL
Intervention: Robot training + Physiotherapy (30 min each for 60 min sessions, 5 days a week for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiotherapy (60 min sessions, 5 days a week for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Robot training + Physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 30
Study: 20082132

Group type: EXPERIMENTAL
Intervention: Multi-electrode array ablation catheters with uninterrupted warfarin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Uninterrupted aspirin
Number of subjects: 81
Study: 18756743

Group type: EXPERIMENTAL
Intervention: Trimetazidine (Preductal MR) in addition to traditional therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetazidine (Preductal MR)
Number of subjects: 0
Study: 16385010

Group type: EXPERIMENTAL
Intervention: High-quality trials with methods such as concealment of allocation, blinding, and outcome assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate funding, good infrastructure, and networks
Number of subjects: 0
Study: 11805921

Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg daily for 5 consecutive days starting 3 days before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10715762

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 124

Group type: COMPARATOR
Intervention: Lignocaine throat spray only
Number of subjects: 124
Study: 8868980

Group type: EXPERIMENTAL
Intervention: Pimobendan 2.5 mg daily
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 1595521

Group type: EXPERIMENTAL
Intervention: Trapidil (600 mg/day orally for 1 week before PTCA and for 4 to 6 months after PTCA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Aspirin (300 mg/day) and dipyridamole (150 mg/day)
Number of subjects: 72
Study: 6705164

Group type: EXPERIMENTAL
Intervention: Ketanserin (2 mg/hr iv, preceded by a 10 mg bolus in three patients)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 5
Study: 31339808

Group type: EXPERIMENTAL
Intervention: Experimental intervention (Word Discovery)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual teaching practice
Number of subjects: 78

Group type: COMPARATOR
Intervention: No intervention words
Number of subjects: 78
Study: 30145269

Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) using video conferencing on a tablet computer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Face-to-face (FTF) visits
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remote delivery (RD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Face-to-face (FTF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) and Face-to-face (FTF)
Number of subjects: 120
Study: 26754679

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pomalidomide 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24802413

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Baseline poor sleep quality
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Baseline tired feeling
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Baseline forgetfulness
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Total number of baseline symptoms (3 to 5 symptoms vs 0 to 2 symptoms)
Number of subjects: 449
Study: 22475889

Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 or 10 mg/day
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 or 10 mg/day (stable responders)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Lu AA21004
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Open-label Lu AA21004
Number of subjects: 687
Study: 20444957

Group type: EXPERIMENTAL
Intervention: Plant sterol therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Plant sterol therapy in mice
Number of subjects: 113
Study: 19235402

Group type: EXPERIMENTAL
Intervention: Visuomotor trail-making task
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Visual search task
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility task
Number of subjects: 54
Study: 16231850

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: In-field radiation therapy (RT)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation and cisplatin- and MOPP-containing therapies
Number of subjects: 757
Study: 12031749

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10071983

Group type: EXPERIMENTAL
Intervention: Etoposide (VP16) at various dose regimens (30 to 200 mg, infusion times 0.5 to 2 h)
Number of subjects: 34
Study: 7985891

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid procollagen III levels
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 3
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 7
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Procollagen III levels of 1.75 U/mL or more on day 14
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Overall fatality rate in patients with ARDS
Number of subjects: 117
Study: 1665493

Group type: EXPERIMENTAL
Intervention: rhGM-CSF 250 micrograms/m2 s.c. on days 4-12
Number of subjects: 30

Group type: COMPARATOR
Intervention: No GM-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGM-CSF starting on day 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AIO chemotherapy (A, 50 mg/m2 on day 1; I, 2 g/m2 on days 1-3; O, 2 mg on day 1) alternating with cisplatin (90 mg/m2 on day 1) and etoposide (150 mg/m2 on days 1-3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AIO chemotherapy (A, Adriamycin 25 mg/m2 on days 1 + 2; I, ifosfamide 2 g/m2 on days 1-5; O, vincristine 2 mg on day 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 30
Study: 6851037

Group type: EXPERIMENTAL
Intervention: i.v. atenolol followed by oral treatment for 10 days
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 477
Study: 30926371

Group type: EXPERIMENTAL
Intervention: Walnut oral immunotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (observation and strict dietary exclusion)
Number of subjects: 73
Study: 30037426

Group type: EXPERIMENTAL
Intervention: High TTR (≥70%)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: NYHA class III and/or IV
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Each 10-point increase in MLWHF score
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Higher number of HF hospitalizations per year
Number of subjects: 1067
Study: 27618825

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 24535791

Group type: EXPERIMENTAL
Intervention: Group L (levobupivacaine) with 20 mL 0.25% levobupivacaine and 40 mg methylprednisolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B (bupivacaine) with 20 mL 0.25% bupivacaine and 40 mg methylprednisolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C (control) with 20 mL physiological saline
Number of subjects: 60
Study: 22334121

Group type: EXPERIMENTAL
Intervention: Intravenous Δ⁹-THC (0.015 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous Δ⁹-THC (0.03 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19581560

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study: 17932908

Group type: EXPERIMENTAL
Intervention: Interferon-alfa 9 million IU 3 times a week
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 9 million IU daily
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Cytokine treatments (interferon-alfa and interleukin-2)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 200 mg daily
Number of subjects: 492
Study: 15804733

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12414028

Group type: EXPERIMENTAL
Intervention: Naso-jejunal enteral feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous crystalloid fluids
Number of subjects: 40
Study: 10788904

Group type: EXPERIMENTAL
Intervention: Community-based educational self-management program for children with asthma
Number of subjects: 0
Study: 7832962

Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 0
Study: 1983780

Group type: EXPERIMENTAL
Intervention: ICI 118,551 (50 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diazepam (2 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7191779

Group type: EXPERIMENTAL
Intervention: Combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pyrazofurin
Number of subjects: 28
Study: 31699176

Group type: EXPERIMENTAL
Intervention: Unconscious Version of the Family Decision-Making Self-Efficacy Scale (FDMSE)
Number of subjects: 215
Study: 30343508

Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg, single daily dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg t.i.d.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both therapies (sildenafil and tadalafil)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 27632051

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary rehabilitation
Number of subjects: 187
Study: 24804989

Group type: EXPERIMENTAL
Intervention: A-NBIME
Number of subjects: 100

Group type: COMPARATOR
Intervention: CV-MCE
Number of subjects: 100
Study: 25622638

Group type: EXPERIMENTAL
Intervention: 1.9 µm Vela Laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-frequency electronic knife
Number of subjects: 30
Study: 21833823

Group type: EXPERIMENTAL
Intervention: Pro-social priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-social priming
Number of subjects: 0
Study: 19278415

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Patient-initiated follow-up
Number of subjects: 4

Group type: COMPARATOR
Intervention: Physician-led follow-up
Number of subjects: 4
Study: 17575230

Group type: EXPERIMENTAL
Intervention: Pemetrexed 600 mg/m2 (P600 arm)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pemetrexed 900 mg/m2 (P900 arm)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High thymidine phosphorylase expression
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low thymidine phosphorylase expression
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High folylpolyglutamate synthetase expression
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low folylpolyglutamate synthetase expression
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High gamma-glutamyl hydrolase expression
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low gamma-glutamyl hydrolase expression
Number of subjects: 92
Study: 15345866

Group type: EXPERIMENTAL
Intervention: Transcervical intrapartum amnioinfusion with saline
Number of subjects: 196

Group type: COMPARATOR
Intervention: Routine obstetrical care
Number of subjects: 196
Study: 11145633

Group type: EXPERIMENTAL
Intervention: Family History Screening Questionnaire (FHSQ) as part of a health check
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health check only (Control)
Number of subjects: 100
Study: 9626829

Group type: EXPERIMENTAL
Intervention: Eptifibatide therapy (135-microg/kg bolus/0.5-microg/kg per min infusion or 135-microg/kg bolus/0.75-microg/kg per min infusion)
Number of subjects: 4010

Group type: COMPARATOR
Intervention: Placebo (placebo bolus/placebo infusion)
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Eptifibatide therapy
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Longer time to sheath removal
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Stent placement with intense post-stent anticoagulation
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: PTCR within 24 h of thrombolytic therapy
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Larger heparin doses during PTCR
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Major coronary dissection
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Placement of a venous sheath
Number of subjects: 4010
Study: 7733514

Group type: EXPERIMENTAL
Intervention: Free amino acid diet (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Partial protein hydrolysate diet (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 20
Study: 2625184

Group type: EXPERIMENTAL
Intervention: Left-sided or total colonoscopy in patients at risk (n = 104)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n = 104)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patients at risk (n = 104)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 810648

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group treated with antirheumatic drugs
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: D-penicillamine and gold treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Immunosuppressive drugs
Number of subjects: 80
Study: 31928034

Group type: EXPERIMENTAL
Intervention: Risk assessment information provided
Number of subjects: 340

Group type: COMPARATOR
Intervention: No risk assessment information provided
Number of subjects: 340
Study: 31000336

Group type: EXPERIMENTAL
Intervention: Honey dressings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 40
Study: 29140383

Group type: EXPERIMENTAL
Intervention: Amnion-Chorion Membranes (ACM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dense Polytetrafluoroethylene Membranes (dPTFE)
Number of subjects: 22
Study: 25072441

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment with antibiotics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 50
Study: 22150529

Group type: EXPERIMENTAL
Intervention: High-frequency words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency words
Number of subjects: 0
Study: 21106651

Group type: EXPERIMENTAL
Intervention: Risk communication (yes)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Social norms communication (yes)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Combined message (risk + social norms)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Risk communication (no)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Social norms communication (no)
Number of subjects: 168
Study: 19222841

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil administered orally twice a day for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matching placebo administered orally twice a day for 12 weeks
Number of subjects: 42
Study: 16863750

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 3099
Study: 12779130

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage and arthroscopic debridement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 11006204

Group type: EXPERIMENTAL
Intervention: 1% nitroprusside gel (5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2% nitroprusside gel (10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 9182442

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy with cisplatin, methotrexate, and vinblastine (CMV) after TUR, aiming for vesical preservation (Arm A, n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chemotherapy with CMV after TUR followed by cystectomy (Arm B, n = 17)
Number of subjects: 37
Study: 8374255

Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Furosemide (50 mg/day)
Number of subjects: 28
Study: 3565115

Group type: EXPERIMENTAL
Intervention: Lay facilitators
Number of subjects: 116

Group type: COMPARATOR
Intervention: Doctoral counseling students
Number of subjects: 116
Study: 30595777

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional radiofrequency
Number of subjects: 118
Study: 26985605

Group type: EXPERIMENTAL
Intervention: Lectures plus print (n=361)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Print (n=357)
Number of subjects: 756
Study: 24935075

Group type: EXPERIMENTAL
Intervention: Senior work-up assessment and treatment (SWAT) model of care
Number of subjects: 1737

Group type: COMPARATOR
Intervention: Non-SWAT control
Number of subjects: 1737

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 1737

Group type: COMPARATOR
Intervention: SWAT, non-SWAT, and standard of care control
Number of subjects: 1737
Study: 23259259

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 151
Study: 20541900

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patches (5, 10, and 20 microg/hour)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Sublingual buprenorphine (200 and 400 microg tablets)
Number of subjects: 246
Study: 18175753

Group type: EXPERIMENTAL
Intervention: Daily chocolate consumption (>=1 time/d)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: <1 time/wk chocolate consumption
Number of subjects: 1001
Study: 16492107

Group type: EXPERIMENTAL
Intervention: 5 nicotine-containing cigarettes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 denicotinized cigarettes
Number of subjects: 60

Group type: COMPARATOR
Intervention: No lapse (abstinence)
Number of subjects: 60
Study: 12773837

Group type: EXPERIMENTAL
Intervention: Children of parents with depression
Number of subjects: 8360

Group type: COMPARATOR
Intervention: Children of parents without depression
Number of subjects: 8360